Search / Trial NCT00001782

Areas of Brain Responsible for Understanding American Sign Language

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of November 28, 2023

Completed

Keywords

Deafness Hemisphere Dominance Language Plasticity Speech R Tms

Description

The purpose of this protocol is to determine if the right hemisphere activation associated with perception of American Sign Language (ASL) in deaf subjects and in normal hearing individuals raised by deaf parents (who learned ASL before written English) is necessary for appropriate understanding of ASL.

Gender

All

Eligibility criteria

  • Subject age between 18 and 65 years.
  • Adult hearing offsprings of deaf parents.
  • Congenitally deaf individuals.
  • Intact hearing volunteers.
  • No subjects with personal or family history of seizures or other neurological or demyelinating disorders.
  • No pregnant women tested after urine pregnancy test.
  • No subjects with severe coronary disease.
  • No subjects with metal in the cranium except mouth.
  • No subjects with intracardiac lines and implanted medication pumps.
  • No subjects with increased intracranial pressure as evaluated by clinical means.
  • No subjects with cardiac pacemakers.
  • No subjects with an intake of neuroleptics.

Attachments

readout_NCT00001782_2023-11-28.pdf

4.5 MB

NCT00001782_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0